Relevant prognostic features of multiple myeloma and the new International Staging System

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 458-468

  Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Gene expression profiling; Genetics; Imaging; International Staging System; Myeloma; Prognosis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CALCIUM; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CREATININE; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ALBUMIN BLOOD LEVEL; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER STAGING; CELL ASSAY; CELL KINETICS; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME 13; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CREATININE BLOOD LEVEL; CYTOGENETICS; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; INTERPHASE; KARYOTYPING; METAPHASE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL; PLASMACYTOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

HUMANS; INTERNATIONALITY; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947658426     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601059753     Document Type: Review

References (60)

1. Durie, B. G. and Salmon, S. E. (1975) A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, pp. 842-854.
2. Salmon, S. E. and Wampler, S. B. (1977) Multiple myeloma: Quantitative staging and assessment of response with a programmable pocket calculator. Blood, 49, pp. 379-389.
3. Cooper, D. A., Miller, A. C. and Penny, R. (1982) Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems. Acta Haematol, 68, pp. 224-236.
4. Blade, J. and Rosinol, L. (2006) Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol, 7, pp. 237-245.
5. Johnson, P. W. and Selby, P. J. (1994) The treatment of multiple myeloma: An important MRC trial. Br J Cancer, 70, pp. 781-785.
6. MacLennan, I. C., Chapman, C., Dunn, J. and Kelly, K. (1992) The Medical Research Council Working Party for Leukaemia in Adults. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 339, pp. 200-205.
7. Durie, B. G. (2006) The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. Eur J Cancer, 42, pp. 1539-1543.
8. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Hayman, S. R. and Kumar, S. K. (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther, 6, pp. 343-360.
9. Bataille, R., Durie, B. G., Grenier, J. and Sany, J. (1986) Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol, 4, pp. 80-87.
10. Scudla, V. and Indrak, K. (1985) Prognostic significance of stratification systems in multiple myeloma. I. Risk categories (good and poor risk). Neoplasm, 32, pp. 469-479.
11. Friedenberg, W. R., Kyle, R. A., Knospe, W. H., Bennet, J. M. and Tsiatis, A. A. (1991) High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol, 36, pp. 171-175.
12. Alexanian, R. (1985) Ten-year survival in multiple myeloma. Arch Intern Med, 145, pp. 2073-2074.
13. Merlini, G., Gobbi, P. G. and Ascari, E. (1989) The Merlini, Waldenström, Jayakar staging system revisited. Eur J Haematol Suppl, 51, pp. 105-110.
14. Drayson, M. T., Chapman, C. E., Dunn, J. A., Olujohungbe, A. B., Maclennan, I. C. and MRC Working Party on Leukaemia in Adults (1998) MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. Br J Haematol, 101, pp. 195-202.
15. Gassmann, W., Pralle, H., Haferlach, T., Pandurevic, S., Graubner, M. and Schmitz, N. (1985) Staging systems for multiple myeloma: A comparison. Br J Haematol, 59, pp. 703-711.
16. Jacobson, J. L., Hussein, M. A., Barlogie, B., Durie, B. G., Crowley, J. J. and Southwest Oncology Group (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol, 122, pp. 441-550.
17. Salmon, S. E., Tesh, D., Crowley, J., Saeed, S., Finley, P. and Milder, M. S. (1990) Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 8, pp. 1575-1584.
18. Salmon, S. E., Crowley, J. J., Grogan, T. M., Finley, P., Pugh, R. P. and Barlogie, B. (1994) Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. J Clin Oncol, 12, pp. 2405-2414.
19. Salmon, S. E., Crowley, J. J., Balcerzak, S. P., Roach, R. W., Taylor, S. A. and Rivkin, S. E. (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study. J Clin Oncol, 16, pp. 890-896.
20. Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D. and Mills, G. M. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 99, pp. 3163-3168.
21. Greipp, P. R., Miguel, J San, Durie, B. G., Crowley, J. J., Barlogie, B. and Blade, J. (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
22. Krejci, M., Buchler, T., Hajek, R., Svobodnik, A., Krivanova, A. and Pour, L. (2005) Prognostic factors for survival after autologous transplantation: A single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant, 35, pp. 159-164.
23. Rajkumar, S. V. and Greipp, P. R. (1999) Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am, 13, pp. 1295-1314.
24. Moulopoulos, L. A., Maris, T. G., Papanikolaou, N., Panagi, G., Vlahos, L. and Dimopoulos, M. A. (2003) Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging. Ann Oncol, 14, pp. 152-158.
25. Lecouvet, F. E., Berg, B C Vande, Malghem, J. and Maldague, B. E. (2001) Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol, 5, pp. 43-55.
26. Ghanem, N., Lohrmann, C., Engelhardt, M., Pache, G., Uhl, M. and Saueressig, U. (2006) Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol, 16, pp. 1005-1014.
27. Baur-Melnyk, A., Buhmann, S., Durr, H. R. and Reiser, M. (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol, 55, pp. 56-63.
28. Moulopoulos, L. A., Gika, D., Anagnostopoulos, A., Delasalle, K., Weber, D. and Alexanian, R. (2005) Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol, 16, pp. 1824-1828.
29. Schirrmeister, H., Bommer, M., Buck, A. K., Muller, S., Messer, P. and Bunjes, D. (2002) Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imag, 29, pp. 361-366.
30. Durie, B. G., Waxman, A. D., D'Agnolo, A. and Williams, C. M. (2002) Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med, 43, pp. 1457-1463.
31. Bredella, M. A., Steinbach, L., Caputo, G., Segall, G. and Hawkins, R. (2005) Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol, 184, pp. 1199-1204.
32. Greipp, P. R., Raymond, N. M., Kyle, R. A. and O'Fallon, W. M. (1985) Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood, 65, pp. 305-310.
33. Greipp, P. R., Leong, T., Bennett, J. M., Gaillard, J. P., Klein, B. and Stewart, J. A. (1998) Plasmablastic morphology: An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood, 91, pp. 2501-2507.
34. Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Therneau, T. M. and Kyle, R. A. (1999) Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol, 17, pp. 1551-1557.
35. Moreau, P., Robillard, N., Avet-Loiseau, H., Pineau, D., Morineau, N. and Milpied, N. (2004) Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica, 89, pp. 547-551.
36. Nowakowski, G. S., Witzig, T. E., Dingli, D., Tracz, M. J., Gertz, M. A. and Lacy, M. Q. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 106, pp. 2276-2279.
37. Gertz, M. A., Lacy, M. Q., Inwards, D. J., Chen, M. G., Pineda, A. A. and Gastineau, D. A. (1999) Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant, 23, pp. 221-226.
38. Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Lust, J. A. and Greipp, P. R. (1999) Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant, 23, pp. 1267-1272.
39. Gertz, M. A., Lacy, M. Q., Inwards, D. J., Gastineau, D. A., Tefferi, A. and Chen, M. G. (2000) Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant, 26, pp. 45-50.
40. Steensma, D. P., Gertz, M. A. Greipp, P. R. Kyle, R. A. Lacy, M. Q. and Lust, J. A. (2001) A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood, 97, pp. 2522-2523.
41. Alexandrakis, M. G., Passam, F. H., Kyriakou, D. S., Dambaki, K., Niniraki, M. and Stathopoulos, E. (2004) Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol, 27, pp. 8-13.
42. Garcia-Sanz, R., Gonzalez-Fraile, M. I., Mateo, G., Hernandez, J. M., Lopez-Berges, M. C. and Heras, N de las (2004) Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer, 112, pp. 884-889.
43. Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S. and Vesole, D. H. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, pp. 4250-4256.
44. Tricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D. and Naucke, S. (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol, 15, pp. 2659-2666.
45. Seong, C., Delasalle, K., Hayes, K., Weber, D., Dimopoulos, M. and Swantkowski, J. (1998) Prognostic value of cytogenetics in multiple myeloma. Br J Haematol, 101, pp. 189-194.
46. Rajkumar, S., Fonseca, R., Lacy, M., Witzig, T., Lust, J. and Greipp, P. (1999) Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant, 24, pp. 497-503.
47. Debes-Marun, C. S. Dewald, G. W., Bryant, S.,Picken, E., Santana-Davila, R. and Gonzalez-Paz, N. (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 17, pp. 427-436.
48. Depil, S., Leleu, X., Micol, J. B., Berthon, C., Lai, L. J. and Bauters, F. (2004) Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk Lymphoma, 45, pp. 2481-2844.
49. Konigsberg, R., Zojer, N., Ackermann, J., Kromer, E., Kittler, H. and Fritz, E. (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol, 18, pp. 804-812.
50. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F. and Zandecki, M. (2001) Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97, pp. 1566-1571.
51. Fonseca, R., Harrington, D., Oken, M. M., Dewald, G. W., Bailey, R. J. and Van Wier, S. A. (2002) Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res, 62, pp. 715-720.
52. Chang, H., Zhuang, L., Nie, E., Bouman, D. and Stewart, A. K. (2004) Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: Comparison with karyotype analysis. Leuk Lymphoma, 45, pp. 965-969.
53. Chiecchio, L., Protheroe, R KM, Ibrahim, A. H., Cheung, K. L., Rudduck, C. and Dagrada, G. P. (2006) on behalf of the UK Myeloma Forum. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 20, pp. 1610-1617.
54. Dewald, G. W., Therneau, T., Larson, D., Lee, Y. K., Fink, S. and Smoley, S. (2005) Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood, 106, pp. 3553-3558.
55. Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Litzow, M. R. and Henderson, K. J. (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 106, pp. 2837-2840.
56. Loiseau, H. A., Attal, M., Moreau, P., Charbonnel, C., Garban, F. and Harousseau, J. L. (2005) A comprehensive analysis of cytogenetic abnormalities in myeloma: Results of the FISH analysis of 1000 patients enrolled in the IFM99 trials. Blood, 106, p. 185a.
57. Bergsagel, P. L. and Kuehl, W. M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol, 23, pp. 6333-6338.
58. Shaughnessy Jr, J. (2003) Primer on medical genomics. Part IX. Scientific and clinical applications of DNA microarrays: Multiple myeloma as a disease model. Mayo Clin Proc, 78, pp. 1098-1109.
59. Claudio, J. O. and Stewart, A. K. (2005) Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am J Pharmacogenomics, 5, pp. 35-43.
60. Stewart, A. K. and Fonseca, R. (2005) Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol, 23, pp. 6339-6344.